This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 2,091 trials Clear all
Filter by:

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Smoking Cessation
    Smoking Cessation
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Zonisamide, Drug: Bupropion, Other: Halo G6 e-cigarette

Eligibility
  • Ages: 21 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Zonisamide, Drug: Bupropion, Other: Halo G6 e-cigarette

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Rose Research Center, Charlotte, North Carolina, United States

Brief Summary

This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline data on use of combustible cigarettes. Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in addition to continued use of the G6. At each visit, participants will receive enough zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6 and combination zonisamide and bupropion use will continue until the participant returns for the End-of-Study visit (V7).

Ultrasound-guided PRP Versus Steroid Injections in Management of Carpal Tunnel Syndrome

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Carpal Tunnel Syndrome
    Carpal Tunnel Syndrome
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: platlet rich plasma (PRP), Drug: Triamcinolone Acetonide, Drug: Saline

Eligibility
  • Ages: 20 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: platlet rich plasma (PRP), Drug: Triamcinolone Acetonide, Drug: Saline

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tanta University Hospital, Tanta, Egypt

Brief Summary

Patients will be randomly divided into 3 equal groups: Group I received ultrasound guided injection of 2 mL PRP into the affected carpal tunnel. Group II received ultrasound guided injection of 2 mL steroids (40 mg triamcinolone acetonide). Group III received ultrasound guided injection of 2 mL saline as placebo control.

An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: Favipiravir, Drug: Standard of Care

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Favipiravir, Drug: Standard of Care

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Republican Clinical Hospital, Makhachkala, Russian Federation

Brief Summary

The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to study during the pivotal stage. The objective of the pivotal stage is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes...
    Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes...
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: aflibercept, Drug: High-dose aflibercept

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: aflibercept, Drug: High-dose aflibercept

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Regeneron Study Site, Phoenix, Arizona, United States

Brief Summary

The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks. The secondary objectives of the study are as follows: - To determine the effect of HD vs. aflibercept on anatomic and other visual measures of response - To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Chronic Hepatitis B
    Chronic Hepatitis B
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beijing Ditan Hospital, Capital Medical University, Beijing, China

Brief Summary

Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon alfa-2b injection, with nucleos(t)ide (NAs), tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B, who has previously treated with nucleos(t)ides and who are treatment naïve.

Immunocompromised Swiss Cohorts Based Trial Platform

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Immunocompromised Patients
    Immunocompromised Patients
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University Hospital Basel, Basel, Switzerland

Brief Summary

This study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative effectiveness and safety of approved SARS-CoV-2 vaccines in immunocompromised patients. This platform will be tested in the frame of an exploratory pilot trial and a framework will be set up to conduct a larger, flexible, randomized controlled trial (RCT) to test approved SARS-CoV-2 vaccines to prevent SARS-CoV-2 infections.

Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: AVIGAN, Drug: Placebo Comparator

Eligibility
  • Ages: 21 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: AVIGAN, Drug: Placebo Comparator

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait

Brief Summary

This is a prospective, interventional, multi-centre, phase III, randomized, double blind, placebo-controlled, parallel design trial to evaluate the efficacy, safety and tolerability of favipiravir as adjunct ('add on') to supportive care, in comparison to placebo with supportive care, in the acute treatment of patients who have tested positive for SARS-CoV-2 and presenting with moderate to severe COVID-19. This study will be conducted in two parts; Stage I - Main study and Stage II - Extended Follow up.

Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Biallelic RPE65 Mutation-associated Retinal Dystrophy
    Biallelic RPE65 Mutation-associated Retinal Dystrophy
  • Phase Phase 3
    Phase 3
INTERVENTION

Genetic: voretigene neparvovec

Eligibility
  • Ages: 4 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Genetic: voretigene neparvovec

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Novartis Investigative Site, Meguro-ku, Tokyo, Japan

Brief Summary

The purpose of this study is to provide safety and efficacy data for voretigene neparvovec, administered as subretinal injection, in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy.

Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19, Burn Out, Post Traumatic Stress Disorder
    Covid19, Burn Out, Post Traumatic Stress Disorder
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: Cannabidiol

Eligibility
  • Ages: 24 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Cannabidiol

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, SP, Brazil

Brief Summary

The objective of this work is to monitor the level of stress and overload of a group of front-line health workers (physicians, nurses and physiotherapists) who will participate in the care of patients with COVID-19 at Hospital das Clínicas in Ribeirão Preto and its Emergency Unit (HCRP), for four weeks, and evaluate the cannabidiol - CBD's effectiveness in reducing stress for those who wish to use it.

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: AZD7442, Drug: Placebo

Eligibility
  • Ages: 18 to 120 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: AZD7442, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Birmingham, Alabama, United States

Brief Summary

This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.